At a glance
ClinicalIndex Comparison RecordN/ACompleted· 217 enrolled
Drug / intervention
Hydrus Microstent +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Hydrus Microstent for Refractory Open-Angle Glaucoma: A Prospective, Multicenter Clinical Trial (Hydrus VII Study)
In Brief
A clinical study evaluating Hydrus Microstent and Ophthalmic surgery for Open-angle Glaucoma. Completed, enrolled 217 participants across 20 sites in 5 countries.
Detailed Summary
The purpose of this study is to assess the safety and effectiveness of the Hydrus Microstent in patients with refractory open-angle glaucoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpen-angle Glaucoma
CountriesColombia, Philippines, Spain, United Kingdom, United States
Collaborators--
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
Enrollment StartAug 2017
First PostedAug 2017
Primary CompletionDec 2022
TodayJul 2026
First PostedAug 30, 2017
Enrollment StartAug 1, 2017
Primary CompletionDec 16, 2022
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 8.8 years ago
Interventions
Hydrus Microstentdevice
Device implanted into the Schlemm's canal of the eye to provide a natural outflow pathway for aqueous humor, leading to a reduction in intraocular pressure (IOP). The Hydrus Microstent is intended for lifetime use of the glaucoma patient.
Ophthalmic surgeryprocedure
Implantation of the Hydrus Microstent performed under either local or topical ophthalmic anesthesia